SB 881 creates a new Maryland regulatory framework for commercial financing transactions offered to businesses, often described as a “small business truth in lending” measure. It defines several types of commercial financing, including open-end financing, closed-end financing, sales-based financing, factoring transactions, and other business-purpose financing, and requires providers to give standardized disclosures before a recipient can proceed. Those disclosures generally include the financing amount, finance charge, annual percentage rate (APR), total repayment amount, repayment term, payment schedule, and any additional fees, collateral requirements, or prepayment-related charges.
The bill also establishes a licensing system for persons engaged in the business of commercial financing in Maryland, unless they are exempt. Beginning January 1, 2027, a person located in the state may not engage in commercial financing without a license from the Commissioner of Financial Regulation or an applicable exemption. The bill sets application, renewal, NMLS registration, trade name, location reporting, and enforcement requirements, and authorizes the Commissioner to adopt regulations, including regulations substantially similar to New York’s commercial financing rules. It also provides civil penalties, criminal penalties for knowing violations by licensees, and authority for the Commissioner, State’s Attorney, or Attorney General to enforce the law.
The bill’s impact on state law is substantial because it adds new subtitles to both the Commercial Law Article and the Financial Institutions Article, creating a dedicated statutory regime for commercial financing disclosures and licensing. It also amends existing law governing the Commissioner’s annual assessments so that revocation, suspension, surrender, or other termination of a license does not eliminate the obligation to pay assessments incurred while the license was valid. In practical terms, the bill affects commercial finance providers, fintech lenders, factoring companies, and other business-purpose lenders, while expressly exempting certain institutions and transactions such as banks, credit unions, real-estate-secured financing, leases, very small-volume providers, and some large-dollar or specialized transactions.
The general sentiment reflected in the bill’s progress appears strongly favorable. The committee report was favorable with amendments, the Senate adopted the bill, and the recorded third reading vote was unanimous at 42-0. That voting history suggests broad bipartisan support for increased transparency and oversight in commercial financing markets.
The main points of contention, based on the bill text itself, are likely to center on compliance burden, disclosure methodology, and the scope of regulation. The bill requires detailed APR calculations, special rules for estimating sales-based financing repayment terms, annual reporting for providers using an opt-in method, and licensing obligations tied to NMLS, all of which may be viewed as burdensome by providers. At the same time, the bill’s exemptions, the treatment of prepayment charges and “double dipping,” and the Commissioner’s authority to adopt regulations similar to New York’s framework are the kinds of provisions that could draw debate from industry stakeholders and consumer/business advocates over how strict the regime should be.
SB 881 adds a new commercial financing disclosure and licensing regime to Maryland law by creating Subtitle 16 of the Commercial Law Article and Subtitle 13 of Title 14 of the Financial Institutions Article. It requires providers of business-purpose financing to make standardized pre-transaction disclosures, regulates APR and repayment calculations, and bars unlicensed commercial financing activity in the state beginning January 1, 2027, subject to exemptions. The bill also expands the Commissioner of Financial Regulation’s enforcement tools, imposes civil and criminal penalties for violations, and modifies assessment rules so license termination does not erase assessment obligations already incurred.
The likely areas of contention are the bill’s regulatory reach and technical compliance requirements. Providers may object to mandatory licensing, NMLS reporting, detailed disclosure forms, APR calculations for multiple financing structures, and annual reporting for certain sales-based financing methods. There may also be debate over the treatment of prepayment charges, the prohibition on presenting non-APR cost metrics as rates, and the Commissioner’s authority to adopt regulations modeled on New York’s commercial financing rules. The bill’s exemptions and carve-outs suggest an effort to narrow the scope, but those boundaries themselves could be disputed by affected lenders and industry groups.